061250 — Hwail Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Hwail Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	108,745	123,613	106,990	132,053	122,541
Cost of Revenue
Gross Profit	14,480	15,034	10,561	13,555	11,519
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	104,812	120,056	103,835	142,717	123,605
Operating Profit	3,933	3,557	3,154	-10,664	-1,064
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,262	4,283	4,440	-7,972	4,898
Provision for Income Taxes
Net Income After Taxes	3,194	2,806	2,842	-6,327	3,863
Net Income Before Extraordinary Items
Net Income	3,194	2,806	2,842	-6,327	3,863
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	3,194	2,806	2,842	-6,327	3,863
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	81.3	67.1	54.9	55	96.2
Dividends per Share